These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36892817)

  • 61. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.
    Castillo V; Figueroa F; González-Pizarro K; Jopia P; Ibacache-Quiroga C
    Foods; 2021 Jul; 10(8):. PubMed ID: 34441497
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-alcoholic fatty liver disease, diet and gut microbiota.
    Finelli C; Tarantino G
    EXCLI J; 2014; 13():461-90. PubMed ID: 26417275
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
    Tokuhara D
    Front Nutr; 2021; 8():700058. PubMed ID: 34250000
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
    Cui Y; Wang Q; Chang R; Zhou X; Xu C
    J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Zhang J; Zhou J; He Z; Li H
    Front Microbiol; 2024; 15():1288856. PubMed ID: 38572244
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
    Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
    Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
    Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
    Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.
    Gupta B; Rai R; Oertel M; Raeman R
    Semin Liver Dis; 2022 May; 42(2):122-137. PubMed ID: 35738255
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    Yahoo N; Dudek M; Knolle P; Heikenwälder M
    J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention.
    Campagnoli LIM; Marchesi N; Vairetti M; Pascale A; Ferrigno A; Barbieri A
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.